Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Short Interest Update

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 18,241 shares, an increase of 34.8% from the January 29th total of 13,527 shares. Based on an average daily trading volume, of 24,613 shares, the short-interest ratio is presently 0.7 days. Approximately 2.0% of the shares of the stock are short sold. Approximately 2.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 24,613 shares, the short-interest ratio is presently 0.7 days.

Virtus LifeSci Biotech Clinical Trials ETF Stock Performance

Shares of Virtus LifeSci Biotech Clinical Trials ETF stock traded down $0.99 on Tuesday, hitting $41.24. 15,089 shares of the company traded hands, compared to its average volume of 24,573. Virtus LifeSci Biotech Clinical Trials ETF has a 12-month low of $13.42 and a 12-month high of $44.10. The firm’s 50-day simple moving average is $40.64 and its 200 day simple moving average is $33.94.

About Virtus LifeSci Biotech Clinical Trials ETF

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.